Literature DB >> 19426966

The anti-inflammatory target A(3) adenosine receptor is over-expressed in rheumatoid arthritis, psoriasis and Crohn's disease.

A Ochaion1, S Bar-Yehuda, S Cohen, F Barer, R Patoka, H Amital, T Reitblat, A Reitblat, J Ophir, I Konfino, Y Chowers, S Ben-Horin, P Fishman.   

Abstract

The Gi protein associated A(3) adenosine receptor (A(3)AR) was recently defined as a novel anti-inflammatory target. The aim of this study was to look at A(3)AR expression levels in peripheral blood mononuclear cells (PBMCs) of patients with autoimmune inflammatory diseases and to explore transcription factors involved receptor expression. Over-expression of A(3)AR was found in PBMCs derived from patients with rheumatoid arthritis (RA), psoriasis and Crohn's disease compared with PBMCs from healthy subjects. Bioinformatics analysis demonstrated the presence of DNA binding sites for nuclear factor-kappaB (NF-kappaB) and cyclic AMP-responsive element binding protein (CREB) in the A(3)AR gene promoter. Up-regulation of NF-kappaB and CREB was found in the PBMCs from patients with RA, psoriasis and Crohn's disease. The PI3K-PKB/Akt signaling pathway, known to regulate both the NF-kappaB and CREB, was also up-regulated in the patients' PBMCs. Taken together, NF-kappaB and CREB are involved with the over-expression of A(3)AR in patients with autoimmune inflammatory diseases. The receptor may be considered as a specific target to combat inflammation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19426966     DOI: 10.1016/j.cellimm.2009.03.020

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  51 in total

1.  Novel fluorescent antagonist as a molecular probe in A(3) adenosine receptor binding assays using flow cytometry.

Authors:  Eszter Kozma; T Santhosh Kumar; Stephanie Federico; Khai Phan; Ramachandran Balasubramanian; Zhan-Guo Gao; Silvia Paoletta; Stefano Moro; Giampiero Spalluto; Kenneth A Jacobson
Journal:  Biochem Pharmacol       Date:  2012-03-01       Impact factor: 5.858

Review 2.  The Purinergic System as a Pharmacological Target for the Treatment of Immune-Mediated Inflammatory Diseases.

Authors:  Luca Antonioli; Corrado Blandizzi; Pál Pacher; György Haskó
Journal:  Pharmacol Rev       Date:  2019-07       Impact factor: 25.468

Review 3.  Potential for developing purinergic drugs for gastrointestinal diseases.

Authors:  Fernando Ochoa-Cortes; Andromeda Liñán-Rico; Kenneth A Jacobson; Fievos L Christofi
Journal:  Inflamm Bowel Dis       Date:  2014-07       Impact factor: 5.325

Review 4.  International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors--an update.

Authors:  Bertil B Fredholm; Adriaan P IJzerman; Kenneth A Jacobson; Joel Linden; Christa E Müller
Journal:  Pharmacol Rev       Date:  2011-02-08       Impact factor: 25.468

5.  Functionally biased modulation of A(3) adenosine receptor agonist efficacy and potency by imidazoquinolinamine allosteric enhancers.

Authors:  Zhan-Guo Gao; Dennis Verzijl; Annelien Zweemer; Kai Ye; Anikó Göblyös; Adriaan P Ijzerman; Kenneth A Jacobson
Journal:  Biochem Pharmacol       Date:  2011-06-21       Impact factor: 5.858

Review 6.  Adenosine and adenosine receptors in the pathogenesis and treatment of rheumatic diseases.

Authors:  Bruce N Cronstein; Michail Sitkovsky
Journal:  Nat Rev Rheumatol       Date:  2016-11-10       Impact factor: 20.543

7.  Baseline adenosine receptor mRNA expression in blood as predictor of response to methotrexate therapy in patients with rheumatoid arthritis.

Authors:  Ankita Singh; Ramnath Misra; Amita Aggarwal
Journal:  Rheumatol Int       Date:  2019-06-15       Impact factor: 2.631

Review 8.  Pharmacological and therapeutic effects of A3 adenosine receptor agonists.

Authors:  Pnina Fishman; Sara Bar-Yehuda; Bruce T Liang; Kenneth A Jacobson
Journal:  Drug Discov Today       Date:  2011-10-19       Impact factor: 7.851

9.  Controlling murine and rat chronic pain through A3 adenosine receptor activation.

Authors:  Zhoumou Chen; Kali Janes; Collin Chen; Tim Doyle; Leesa Bryant; Dilip K Tosh; Kenneth A Jacobson; Daniela Salvemini
Journal:  FASEB J       Date:  2012-02-17       Impact factor: 5.191

Review 10.  Adenosine receptors as drug targets--what are the challenges?

Authors:  Jiang-Fan Chen; Holger K Eltzschig; Bertil B Fredholm
Journal:  Nat Rev Drug Discov       Date:  2013-04       Impact factor: 84.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.